TY - JOUR AU - Strand, V. AU - Singh, J. A. PY - 2010 DA - 2010// TI - Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity JO - Drugs. VL - 70 UR - https://doi.org/10.2165/11531980-000000000-00000 DO - 10.2165/11531980-000000000-00000 ID - Strand2010 ER - TY - JOUR AU - Strand, V. AU - Khanna, D. PY - 2010 DA - 2010// TI - The impact of rheumatoid arthritis and treatment on patients' lives JO - Clin Exp Rheumatol. VL - 28 ID - Strand2010 ER - TY - JOUR AU - Kirwan, J. R. AU - Hewlett, S. E. AU - Heiberg, T. AU - Hughes, R. A. AU - Carr, M. AU - Hehir, M. PY - 2005 DA - 2005// TI - Incorporating the patient perspective into outcome assessment in rheumatoid arthritis–progress at OMERACT 7 JO - J Rheumatol. VL - 32 ID - Kirwan2005 ER - TY - STD TI - US Dept of Health, FDA, CDER C, CDRH. Guidance for Industry Patient-Reported Outcome Measures. In: Use in Medical Product Development to Support Labeling Claims. 2009. p. 1–39. ID - ref4 ER - TY - STD TI - European Medicines Agency: Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products [http://www.ispor.org/workpaper/emea-hrql-guidance.pdf]. UR - http://www.ispor.org/workpaper/emea-hrql-guidance.pdf ID - ref5 ER - TY - JOUR AU - Bellamy, N. AU - Boers, M. AU - Felson, D. AU - Fries, J. AU - Furst, D. AU - Henry, D. PY - 1995 DA - 1995// TI - Health status instruments/utilities JO - J Rheumatol. VL - 22 ID - Bellamy1995 ER - TY - JOUR AU - Kirwan, J. R. AU - Minnock, P. AU - Adebajo, A. AU - Bresnihan, B. AU - Choy, E. AU - Wit, M. PY - 2007 DA - 2007// TI - Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis JO - J Rheumatol. VL - 34 ID - Kirwan2007 ER - TY - JOUR AU - Strand, V. AU - Boers, M. AU - Idzerda, L. AU - Kirwan, J. R. AU - Kvien, T. K. AU - Tugwell, P. S. PY - 2011 DA - 2011// TI - It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10 JO - J Rheumatol VL - 38 UR - https://doi.org/10.3899/jrheum.110392 DO - 10.3899/jrheum.110392 ID - Strand2011 ER - TY - JOUR AU - Smolen, J. S. AU - Landewe, R. AU - Breedveld, F. C. AU - Buch, M. AU - Burmester, G. AU - Dougados, M. PY - 2014 DA - 2014// TI - EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update JO - Ann Rheum Dis. VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204573 DO - 10.1136/annrheumdis-2013-204573 ID - Smolen2014 ER - TY - JOUR AU - O'Dell, J. R. PY - 2004 DA - 2004// TI - Therapeutic strategies for rheumatoid arthritis JO - N Engl J Med. VL - 350 UR - https://doi.org/10.1056/NEJMra040226 DO - 10.1056/NEJMra040226 ID - O'Dell2004 ER - TY - JOUR AU - Bathon, J. M. AU - Cohen, S. B. PY - 2008 DA - 2008// TI - The, American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road JO - Arthritis Rheum VL - 2008 UR - https://doi.org/10.1002/art.23723 DO - 10.1002/art.23723 ID - Bathon2008 ER - TY - JOUR AU - Saag, K. G. AU - Teng, G. G. AU - Patkar, N. M. AU - Anuntiyo, J. AU - Finney, C. AU - Curtis, J. R. PY - 2008 DA - 2008// TI - American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis JO - Arthritis Rheum. VL - 59 UR - https://doi.org/10.1002/art.23721 DO - 10.1002/art.23721 ID - Saag2008 ER - TY - JOUR AU - Meyer, D. M. AU - Jesson, M. I. AU - Li, X. AU - Elrick, M. M. AU - Funckes-Shippy, C. L. AU - Warner, J. D. PY - 2010 DA - 2010// TI - Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis JO - J Inflamm (Lond) VL - 7 UR - https://doi.org/10.1186/1476-9255-7-41 DO - 10.1186/1476-9255-7-41 ID - Meyer2010 ER - TY - JOUR AU - Kremer, J. M. AU - Cohen, S. AU - Wilkinson, B. E. AU - Connell, C. A. AU - French, J. L. AU - Gomez-Reino, J. PY - 2012 DA - 2012// TI - A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone JO - Arthritis Rheum. VL - 64 UR - https://doi.org/10.1002/art.33419 DO - 10.1002/art.33419 ID - Kremer2012 ER - TY - JOUR AU - Kremer, J. M. AU - Bloom, B. J. AU - Breedveld, F. C. AU - Coombs, J. H. AU - Fletcher, M. P. AU - Gruben, D. PY - 2009 DA - 2009// TI - The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo JO - Arthritis Rheum. VL - 60 UR - https://doi.org/10.1002/art.24567 DO - 10.1002/art.24567 ID - Kremer2009 ER - TY - JOUR AU - Fleischmann, R. AU - Cutolo, M. AU - Genovese, M. C. AU - Lee, E. B. AU - Kanik, K. S. AU - Sadis, S. PY - 2012 DA - 2012// TI - Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs JO - Arthritis Rheum. VL - 64 UR - https://doi.org/10.1002/art.33383 DO - 10.1002/art.33383 ID - Fleischmann2012 ER - TY - JOUR AU - Tanaka, Y. AU - Suzuki, M. AU - Nakamura, H. AU - Toyoizumi, S. AU - Zwillich, S. H. PY - 2011 DA - 2011// TI - Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate JO - Arthritis Care Res (Hoboken) VL - 63 UR - https://doi.org/10.1002/acr.20494 DO - 10.1002/acr.20494 ID - Tanaka2011 ER - TY - JOUR AU - Tanaka, Y. AU - Takeuchi, T. AU - Yamanaka, H. AU - Nakamura, H. AU - Toyoizumi, S. AU - Zwillich, S. PY - 2015 DA - 2015// TI - Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week randomized, phase 2 study JO - Mod Rehumatol VL - 25 UR - https://doi.org/10.3109/14397595.2014.995875 DO - 10.3109/14397595.2014.995875 ID - Tanaka2015 ER - TY - JOUR AU - Lee, E. B. AU - Fleischmann, R. AU - Hall, S. AU - Wilkinson, B. AU - Bradley, J. AU - Gruben, D. PY - 2014 DA - 2014// TI - Tofacitinib versus methotrexate in rheumatoid arthritis JO - N Engl J Med. VL - 370 UR - https://doi.org/10.1056/NEJMoa1310476 DO - 10.1056/NEJMoa1310476 ID - Lee2014 ER - TY - JOUR AU - Burmester, G. R. AU - Blanco, R. AU - Charles-Schoeman, C. AU - Wollenhaupt, J. AU - Zerbini, C. AU - Benda, B. PY - 2013 DA - 2013// TI - Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial JO - Lancet. VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61424-X DO - 10.1016/S0140-6736(12)61424-X ID - Burmester2013 ER - TY - JOUR AU - Fleischmann, R. AU - Kremer, J. AU - Cush, J. AU - Schulze-Koops, H. AU - Connell, C. A. AU - Bradley, J. D. PY - 2012 DA - 2012// TI - Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis JO - N Engl J Med. VL - 367 UR - https://doi.org/10.1056/NEJMoa1109071 DO - 10.1056/NEJMoa1109071 ID - Fleischmann2012 ER - TY - JOUR AU - Heijde, D. AU - Tanaka, Y. AU - Fleischmann, R. AU - Keystone, E. AU - Kremer, J. AU - Zerbini, C. PY - 2013 DA - 2013// TI - Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study JO - Arthritis Rheum. VL - 65 UR - https://doi.org/10.1002/art.37816 DO - 10.1002/art.37816 ID - Heijde2013 ER - TY - JOUR AU - Vollenhoven, R. F. AU - Fleischmann, R. AU - Cohen, S. AU - Lee, E. B. AU - García Meijide, J. A. AU - Wagner, S. PY - 2012 DA - 2012// TI - Tofacitinib or adalimumab versus placebo in rheumatoid arthritis JO - N Engl J Med. VL - 367 UR - https://doi.org/10.1056/NEJMoa1112072 DO - 10.1056/NEJMoa1112072 ID - Vollenhoven2012 ER - TY - JOUR AU - Kremer, J. AU - Li, Z. G. AU - Hall, S. AU - Fleischmann, R. AU - Genovese, M. AU - Martin-Mola, E. PY - 2013 DA - 2013// TI - Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial JO - Ann Intern Med. VL - 159 UR - https://doi.org/10.7326/0003-4819-159-4-201308200-00006 DO - 10.7326/0003-4819-159-4-201308200-00006 ID - Kremer2013 ER - TY - JOUR AU - Wollenhaupt, J. AU - Silverfield, J. AU - Lee, E. B. AU - Curtis, J. R. AU - Wood, S. P. AU - Soma, K. PY - 2014 DA - 2014// TI - Safety and efficacy of tofacitinib, an oral Janus kinase Inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies JO - J Rheumatol. VL - 41 UR - https://doi.org/10.3899/jrheum.130683 DO - 10.3899/jrheum.130683 ID - Wollenhaupt2014 ER - TY - JOUR AU - Wollenhaupt, J. AU - Silverfield, J. AU - Lee, E. N. AU - Terry, K. AU - Kwok, K. AU - Lazariciu, I. PY - 2015 DA - 2015// TI - Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years JO - Arthritis Rheum VL - 67 ID - Wollenhaupt2015 ER - TY - JOUR AU - Wells, G. A. AU - Tugwell, P. AU - Kraag, G. R. AU - Baker, P. R. AU - Groh, J. AU - Redelmeier, D. A. PY - 1993 DA - 1993// TI - Minimum important difference between patients with rheumatoid arthritis: the patient's perspective JO - J Rheumatol. VL - 20 ID - Wells1993 ER - TY - JOUR AU - Wells, G. AU - Li, T. AU - Maxwell, L. AU - Maclean, R. AU - Tugwell, P. PY - 2007 DA - 2007// TI - Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis JO - J Rheumatol. VL - 34 ID - Wells2007 ER - TY - JOUR AU - Farrar, J. T. AU - Young, J. P. AU - LaMoreaux, L. AU - Werth, J. L. AU - Poole, R. M. PY - 2001 DA - 2001// TI - Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale JO - Pain. VL - 94 UR - https://doi.org/10.1016/S0304-3959(01)00349-9 DO - 10.1016/S0304-3959(01)00349-9 ID - Farrar2001 ER - TY - JOUR AU - Dworkin, R. H. AU - Turk, D. C. AU - Wyrwich, K. W. AU - Beaton, D. AU - Cleeland, C. S. AU - Farrar, J. T. PY - 2008 DA - 2008// TI - Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations JO - J Pain. VL - 9 UR - https://doi.org/10.1016/j.jpain.2007.09.005 DO - 10.1016/j.jpain.2007.09.005 ID - Dworkin2008 ER - TY - JOUR AU - Boyle, M. H. AU - Furlong, W. AU - Feeny, D. AU - Torrance, G. W. AU - Hatcher, J. PY - 1995 DA - 1995// TI - Reliability of the Health Utilities Index--Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire JO - Qual Life Res. VL - 4 UR - https://doi.org/10.1007/BF02260864 DO - 10.1007/BF02260864 ID - Boyle1995 ER - TY - JOUR AU - Kosinski, M. AU - Zhao, S. Z. AU - Dedhiya, S. AU - Osterhaus, J. T. AU - Ware, J. E. PY - 2000 DA - 2000// TI - Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis JO - Arthritis Rheum. VL - 43 UR - https://doi.org/3.0.CO;2-M DO - 3.0.CO;2-M ID - Kosinski2000 ER - TY - JOUR AU - Strand, V. AU - Bombardier, C. AU - Maetzel, A. PY - 2001 DA - 2001// TI - Use of minimum clinically important differences [MCID] in evaluating patient responses to treatment of RA [abstract] JO - Arthritis Rheum VL - 44 ID - Strand2001 ER - TY - JOUR AU - Strand, V. AU - Cannon, G. AU - Cohen, S. AU - Ware, J. PY - 2001 DA - 2001// TI - Correlation of HAQ with SF-36; comparison of leflunomide to methotrexate in patients with active RA [abstract] JO - Arthritis Rheum VL - 44 ID - Strand2001 ER - TY - JOUR AU - Zhao, S. Z. AU - Fiechtner, J. I. AU - Tindall, E. A. AU - Dedhiya, S. D. AU - Zhao, W. W. AU - Osterhaus, J. T. PY - 2000 DA - 2000// TI - Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib JO - Arthritis Care Res. VL - 13 UR - https://doi.org/3.0.CO;2-L DO - 3.0.CO;2-L ID - Zhao2000 ER - TY - JOUR AU - Tugwell, P. AU - Wells, G. AU - Strand, V. AU - Maetzel, A. AU - Bombardier, C. AU - Crawford, B. PY - 2000 DA - 2000// TI - Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group JO - Arthritis Rheum VL - 43 UR - https://doi.org/3.0.CO;2-U DO - 3.0.CO;2-U ID - Tugwell2000 ER - TY - JOUR AU - Wells, G. AU - Li, T. AU - Maxwell, L. AU - Maclean, R. AU - Tugwell, P. PY - 2008 DA - 2008// TI - Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis JO - Ann Rheum Dis. VL - 67 UR - https://doi.org/10.1136/ard.2007.069690 DO - 10.1136/ard.2007.069690 ID - Wells2008 ER - TY - BOOK AU - Ware, J. E. AU - Kosinski, M. AU - Dewey, J. E. PY - 2000 DA - 2000// TI - How to score version two of the SF 36 Health Survey PB - Quality Metric, Incorporate CY - Lincoln, RI ID - Ware2000 ER - TY - JOUR AU - Strand, V. AU - Crawford, B. AU - Singh, J. AU - Choy, E. AU - Smolen, J. S. AU - Khanna, D. PY - 2009 DA - 2009// TI - Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases JO - Ann Rheum Dis. VL - 68 UR - https://doi.org/10.1136/ard.2009.115550 DO - 10.1136/ard.2009.115550 ID - Strand2009 ER - TY - JOUR AU - Pincus, T. PY - 2010 DA - 2010// TI - Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care? JO - Bull NYU Hosp Jt Dis. VL - 68 ID - Pincus2010 ER - TY - JOUR AU - Carr, A. AU - Hewlett, S. AU - Hughes, R. AU - Mitchell, H. AU - Ryan, S. AU - Carr, M. PY - 2003 DA - 2003// TI - Rheumatology outcomes: the patient's perspective JO - J Rheumatol. VL - 30 ID - Carr2003 ER - TY - JOUR AU - Dickens, C. AU - McGowan, L. AU - Clark-Carter, D. AU - Creed, F. PY - 2002 DA - 2002// TI - Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis JO - Psychosom Med. VL - 64 UR - https://doi.org/10.1097/00006842-200201000-00008 DO - 10.1097/00006842-200201000-00008 ID - Dickens2002 ER - TY - JOUR AU - Uguz, F. AU - Akman, C. AU - Kucuksarac, S. AU - Tufekci, O. PY - 2009 DA - 2009// TI - Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis JO - Psychiatry Clin Neurosci. VL - 63 UR - https://doi.org/10.1111/j.1440-1819.2008.01905.x DO - 10.1111/j.1440-1819.2008.01905.x ID - Uguz2009 ER -